Photothrombosis of Corneal Neovascularization by Photodynamic Therapy Utilizing Verteporfin and Diode Laser
Journal of Lasers in Medical Sciences,
Vol. 4 No. 3 (2013),
22 June 2013
Introduction: The aim of the present study was to evaluate the effect of photodynamic therapy in the treatment of experimental corneal neovascularization (NV) with benzoporphyrin derivative (BPD).
Methods: One group was considered as control (n=6 eyes) then, corneal NV was induced in 30 New Zealand male rabbits (n=60 eyes) by placing 7.0 silk sutures at midstromal depth approximately1mm from the limbus. Fifteen rabbits with corneal NV were left without any treatment, and 15 rabbits were subjected to photodynamic therapy (PDT) by intravenous injection with Verteporfin at a dose of 1.5 mg /Kg. Diode laser (660 nm) was applied after 15minutes for 5 minutes with a power of 50 mW/cm2. All rabbits were successively followed up by slit lamp examination for periods of 1 day, 1, 2, 3 and 4 weeks. Three rabbits were selected and sacrificed weekly (n=6 eyes each) and the corneas were isolated for histopathological examination.
Results: The results of slit lamp examination indicated the gradual regression of the cornea neovascularization 4 weeks of PDT. Furthermore, regression of corneal neovascularization was documented clinically by decrease number and length of blood vessels and by histopathological examination.
Conclusion: PDT with Verteporfin can provide efficacious treatment of corneal neovascularization.
- corneal neovascularizations
- photodynamic therapy
- diode laser
How to Cite
Cassin B, Solomon S. Dictionary of Eye Terminology. Triad Publishing Company, Gainsville, Florida.1990.
Faraj LA, Said DG, Dua HS. Evaluation of corneal neovascularization. Br J Ophthalomol 2011; 95:1343-4.
Lee P, Wang CC, Adamis AP. Ocular neovascularization an epidemiologic review. Surv Ophthalmol 1998; 43: 245-69.
ARVO. The Association for Research in Vision and Ophthalmology Inc. Invest Ophthalmol Vis Sci 2008; 49: 894-9.
Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal neovascularization: Pathogenesis and inhibition.Cornea 1987; 6: 250-7.
Nirankar i VS, Bear JC. Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty. Ophthalmology 1986; 93: 1304-9.
Marsh R J. Argon laser treatment of lipid keratopathy. Br J Ophthalmol 1988; 72: 900-904.
Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmaco Ther 2007; 41: 614-25.
Hosseini H, Nejabat M. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med Hypotheses 2007; 68:799-801.
Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical Bevacizumab on corneal neovascularization. Ophthalmology 2008; 115: 33-8.
Gohto Y, Obana A, Kaneda K, Nakajima S, TakemuraТ, Miki T. Accumulation of photosensitizer ATX- S10 (Na) in experimental corneal neovascularization. Jpn J ophthalmol 2000; 44: 348-53.
Gohto Y, Obana A, Kanai M, Nagata S, Miki T, Nakajima S. Photodynamic therapy for corneal neovascularization using topically administered ATX- S10 (Na). Ophthalmic Sur Lasers 2000; 31: 55- 60.
Nowak-Sliwinska P, Karocki A, Elas M, Pawlak A, Stochel G, Urbanska K. Verteporfin, photofrin II, and merocyanine 540 as PDT photosensitizers against melanoma cells. Biochem Biophys Res Commun 2006; 349: 549-55.
Chan WM, Lim TH, Pece A, Silva R, Yoshimura N. Verteporfin PDT for non-standard indications- a review of current literature. Graefes Arch Clin Exp Ophthalmol 2010; 248: 613-26.
Schmidt - Erfurth U, Hasan T, Schomacker k, Flotte T, Birngruber R. In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Laser Surg Med 1995; 17, 178-188.
Cursiefen C, Wenkel H, Martus P, Langenbucher A, Nguyen NX, Seitz B, et al. Impact of short-term versus long- term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol 2001; 239: 514-21.
Snedecore GW, Cochran WG. Statistical Methods, 6th ed. Ames., Iowa, USA. 1976.
Ichikawa K, Takeuchi Y, Yonezawa S, Hikita T, Kurohane K, Namba Y, et al. Antiangiogenic photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth. Cancer Lett 2004; 205: 39-48.
De Smidt PC, Verslus AJ, van Berkel TJ. Properties of incorporation, redistribution, and integrity of porphyrinlow- density lipoprotein complexes. Biochemistry 1993; 32: 2916-22.
Koller-Lucae SK, Schott H, Schwendener RA. Low-density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-β-D-arabinofuranosylcytosine in Daudi lymphoma cells. Br J Cancer 1999; 80:1542-9.
Pan G, Oie S, Lu DR. Uptake of the carborane derivative of cholesteryl ester by glioma cancer cells is mediated through LDL receptors. Pharm Res 2004; 21: 1257-62.
Lukšienė Ž. Photodynamic therapy: mechanism of action and ways to improve the efficiency of treatment. Medicina 2003; 39: 1137-50.
Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992; 55:145-57.
Yanik M, Erel O, Kati M. The relationship between potency of oxidative stress and severity of depression. Acta Neuropsychiatr 2004; 16: 200-3.
Harma M, Harma M, Erel O. Oxidative stress in women with preeclampsia. Am J Obstet Gynecol 2005; 192: 656–7.
Yeni E, Gulum M, Selek S, Erel O, Unal D, Verit A, et al. Comparison of oxidative/antioxidative status of penile corpus cavernosum blood and peripheral venous blood. Int J Impot Res 2005; 17:19-22.
Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V. Method for the measurement of antioxidant activity in human fluids. J Clin Pathol 2001; 54:356-61.
Koksal H, Kurban S. Total oxidant status, total antioxidant status, and paraoxonase and arylesterase activities during laparoscopic cholecystectomy. Clinics 2010; 65:285-90.
Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103-11.
Demirbag R, Gur M, Yilmaz R, Kunt AS, Erel O, Andac MH. Influence of oxidative stress on the development of collateral circulation in total coronary occlusions. Int J Cardiol 2007;116: 14-9.
Rabus M, Demirbağ R, Sezen Y, Konukoğlu O, Yildiz A, Erel Ö, et al. Plasma and tissue oxidative stress index in patients with rheumatic and degenerative heart valve disease. Arch Turk Soc Cardiol 2008; 36: 536-540.
Bortner CD, Cidlowski JA. Cellular mechanisms for the repression of apoptosis. Ann Rev Pharmacol Toxicol 2002; 42:259-81.
- Abstract Viewed: 354 times
- PDF Downloaded: 178 times